FDG-PET in 10 children with non-Hodgkin's lymphoma: Initial experience in staging and follow-up

Klinische Padiatrie

Volumn 217, Issue 6, 2005, Pages 327-333

  Amthauer, Holger ^a   Furth, C ^a   Denecke, T ^a   Hundsdoerfer, P ^b   Voelker, T ^a   Seeger, K ^a   Stover B ^a   Henze, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Non Hodgkin lymphoma in childhood; Pet; Staging; Therapy assessment; Tumour recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; CHILD; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; FOLLOW UP; HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; TIME SERIES ANALYSIS; TUMOR DIAGNOSIS; TUMOR RECURRENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 28544439031     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872517     Document Type: Review

References (27)

1. 18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267
2. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, der Walt J van, Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-3346
3. Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients? Ann Oncol 1999; 10: 1141-1143
4. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-1063
5. Hahn K, Fischer S. Strahlenexposition und Strahlenschutz bei nuklearmedizinischen Untersuchungen in der Pädiatrie. Nuklearmediziner 2002; 25: 90-100
6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392
7. Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jurgens H, Schober O, Franzius C. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 2005; 44: -7
8. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433
9. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618
10. Knapp WH. Leitlinie zur Tumordarstellung mit (F-18)-Fluorodeoxyglukose (FDG). www.nuklearmedizin.de/publikationen/leitlinien/ tumo_darst.php
11. Korholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, Dorffel W, Wickmann L, Papsdorf K, Dieckmann K, Kahn T, Mauz-Korholz C, Dannenberg C, Potter R, Brosteanu O, Schellong G, Sabri O. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 50-156
12. Lieberz D, Sextro M, Paulus U, Franklin J, Tesch H, Diehl V. How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Hematol 2000; 79: 73-78
13. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800
14. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543-553
15. 18F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29: 1155-1165
16. Murphy SB, Hustu HO, Rivera G, Berard CW. End results of treating children with localized non-Hodgkin's lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1983; 1: 326-330
17. Ng YY, Healy JC, Vincent JM, Kingston JE, Armstrong P, Reznek RH. The radiology of non-Hodgkin's lymphoma in childhood: a review of 80 cases. Clin Radiol 1994; 49: 594-600
18. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273-1279
19. Pfistner B, Mehl C, Kloss M, Loffler M, Herrmann-Frank A, Diehl V. Quality standards and their assurance for study centers in the competence network malignant lymphoma. Klin Padiatr 2003; 215: 341-344
20. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, Sykora KW, Ludwig WD, Gadner H, Riehm H. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-372
21. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723
22. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S89-S96
23. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): 82-88
24. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419
25. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363
26. 18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): 97-105
27. Wickmann L, Luders H, Dorffel W. [18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations]. Klin Padiatr 2003; 215: 146-150